AZN.L
AstraZeneca
Health Care · Pharmaceuticals · LSE
$13,836.00
Data: 2026-05-09
✓ ETHICAL PASS
Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$206.9B
Total market value of the company
Rev Growth
+12.5%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About AstraZeneca
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
25.6% PASS
Debt must be below 33% of total assets
Cash Ratio
5.0% PASS
Interest-bearing cash below 33% of assets
Receivables
9.0% PASS
Receivables below 49% of assets
Revenue Purity
2.1% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
AVOID
Overall assessment combining ethics, valuation, and quality
Ethical Score
80.9
Valuation Score
55.0
Quality Score
54.0
Combined
64.5
Trading at $13344, 146% above fair value of $5428. Passes all ethical screens. Ranks better than 48% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
7.7%
Historical annualised return based on price data
Days in State
142
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Soriot (Pascal) | 18,359 | — | ||
| 2026-03-05 | Soriot (Pascal) | 101,495 | — | ||
| 2026-03-04 | Sarin (Aradhana M.D.) | 4,863 | — | ||
| 2026-03-04 | Soriot (Pascal) | 14,967 | — | ||
| 2026-01-31 | The Capital Group Companies, Inc. | — | — | ||
| 2026-01-31 | Wellington Management Company, L.L.P. | — | — | ||
| 2026-01-31 | Investor AB | — | — | ||
| 2026-01-31 | BlackRock Financial Management, Inc. | — | — | ||
| 2025-12-31 | Ashley (Euan) | — | — | ||
| 2025-12-31 | BlackRock Financial Management, Inc. | — | — |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09